213 related articles for article (PubMed ID: 8245467)
1. Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.
Lamousé-Smith E; Clements VK; Ostrand-Rosenberg S
J Immunol; 1993 Dec; 151(11):6283-90. PubMed ID: 8245467
[TBL] [Abstract][Full Text] [Related]
2. Apparent split tolerance of CD8+ T cells from beta 2-microglobulin-deficient (beta 2m-/-) mice to syngeneic beta 2m+/+ cells.
Jhaver KG; Rao TD; Frey AB; Vukmanović S
J Immunol; 1995 Jun; 154(12):6252-61. PubMed ID: 7759863
[TBL] [Abstract][Full Text] [Related]
3. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
Yoshimura A; Shiku H; Nakayama E
J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
[TBL] [Abstract][Full Text] [Related]
4. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
Tomita Y; Mayumi H; Eto M; Nomoto K
J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
[TBL] [Abstract][Full Text] [Related]
5. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells.
Apasov SG; Sitkovsky MV
J Immunol; 1994 Mar; 152(5):2087-97. PubMed ID: 8133027
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
[TBL] [Abstract][Full Text] [Related]
7. Increased number of cytotoxic T cells within CD4+8- T cells in beta 2-microglobulin, major histocompatibility complex class I-deficient mice.
Marusić-Galesić S; Udaka K; Walden P
Eur J Immunol; 1993 Dec; 23(12):3115-9. PubMed ID: 8258325
[TBL] [Abstract][Full Text] [Related]
8. Allospecific cytotoxic T cells generated from beta 2m-/- mice in primary MLC: analysis of activation requirements, specificity, and phenotype.
Lamousé-Smith E; McCarthy SA
Cell Immunol; 1997 Aug; 179(2):107-15. PubMed ID: 9268494
[TBL] [Abstract][Full Text] [Related]
9. CD4-negative cytotoxic T cells with a T cell receptor alpha/beta intermediate expression in CD8-deficient mice.
Dalloul AH; Ngo K; Fung-Leung WP
Eur J Immunol; 1996 Jan; 26(1):213-8. PubMed ID: 8566069
[TBL] [Abstract][Full Text] [Related]
10. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
[TBL] [Abstract][Full Text] [Related]
11. Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells.
Hou S; Doherty PC; Zijlstra M; Jaenisch R; Katz JM
J Immunol; 1992 Aug; 149(4):1319-25. PubMed ID: 1354233
[TBL] [Abstract][Full Text] [Related]
12. CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells.
Monach PA; Schreiber H; Rowley DA
Transplantation; 1993 Jun; 55(6):1356-61. PubMed ID: 8100090
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
Ellenhorn JD; Schreiber H; Bluestone JA
J Immunol; 1990 Apr; 144(7):2840-6. PubMed ID: 1969454
[TBL] [Abstract][Full Text] [Related]
14. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
15. Studies with MHC-deficient knock-out mice reveal impact of both MHC I- and MHC II-dependent T cell responses on Listeria monocytogenes infection.
Ladel CH; Flesch IE; Arnoldi J; Kaufmann SH
J Immunol; 1994 Oct; 153(7):3116-22. PubMed ID: 7726898
[TBL] [Abstract][Full Text] [Related]
16. Sufficiency of the CD8+ T cell lineage to mount an effective tumoricidal response to syngeneic tumor-bearing novel class I MHC antigens.
Fan ST; Edgington TS
J Immunol; 1989 Dec; 143(12):4287-91. PubMed ID: 2531780
[TBL] [Abstract][Full Text] [Related]
17. Beta 2-microglobulin-dependent T cells are not necessary for alloantigen-induced Th2 responses after neonatal induction of lymphoid chimerism in mice.
Foucras G; Coureau C; Beijleveld L; Druet P; Saoudi A; Guéry JC
J Immunol; 1998 Aug; 161(4):1751-7. PubMed ID: 9712040
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection.
Tarleton RL; Koller BH; Latour A; Postan M
Nature; 1992 Mar; 356(6367):338-40. PubMed ID: 1549177
[TBL] [Abstract][Full Text] [Related]
19. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
Margenthaler JA; Flye MW
J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
[TBL] [Abstract][Full Text] [Related]
20. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
